867 related articles for article (PubMed ID: 19370562)
61. Ginkgo biloba for cognitive impairment and dementia.
Birks J; Grimley Evans J
Cochrane Database Syst Rev; 2009 Jan; (1):CD003120. PubMed ID: 19160216
[TBL] [Abstract][Full Text] [Related]
62. A 24-week, multicentre, open evaluation of the clinical effectiveness of the rivastigmine patch in patients with probable Alzheimer's disease.
Articus K; Baier M; Tracik F; Kühn F; Preuss UW; Kurz A
Int J Clin Pract; 2011 Jul; 65(7):790-6. PubMed ID: 21645184
[TBL] [Abstract][Full Text] [Related]
63. Folic acid with or without vitamin B12 for the prevention and treatment of healthy elderly and demented people.
Malouf R; Grimley Evans J
Cochrane Database Syst Rev; 2008 Oct; (4):CD004514. PubMed ID: 18843658
[TBL] [Abstract][Full Text] [Related]
64. Sixteen-Week Interventional Study to Evaluate the Clinical Effects and Safety of Rivastigmine Capsules in Chinese Patients with Alzheimer's Disease.
Jia J; Ji Y; Feng T; Ye Q; Peng D; Kuang W; Ning Y; Liang Z; Fan D; Wei W; Li Y; Xiao S
J Alzheimers Dis; 2019; 72(4):1313-1322. PubMed ID: 31744005
[TBL] [Abstract][Full Text] [Related]
65. Nimodipine for primary degenerative, mixed and vascular dementia.
López-Arrieta JM; Birks J
Cochrane Database Syst Rev; 2002; (3):CD000147. PubMed ID: 12137606
[TBL] [Abstract][Full Text] [Related]
66. Cholinesterase inhibitors in the treatment of Alzheimer's disease: a comparison of tolerability and pharmacology.
Nordberg A; Svensson AL
Drug Saf; 1998 Dec; 19(6):465-80. PubMed ID: 9880090
[TBL] [Abstract][Full Text] [Related]
67. Pharmacodynamic-tolerability relationships of cholinesterase inhibitors for Alzheimer's disease.
Imbimbo BP
CNS Drugs; 2001; 15(5):375-90. PubMed ID: 11475943
[TBL] [Abstract][Full Text] [Related]
68. Efficacy of higher dose 13.3 mg/24 h rivastigmine patch on instrumental activities of daily living in patients with mild-to-moderate Alzheimer's disease.
Grossberg G; Cummings J; Frölich L; Bellelli G; Molinuevo JL; Krahnke T; Strohmaier C
Am J Alzheimers Dis Other Demen; 2013 Sep; 28(6):583-91. PubMed ID: 23982674
[TBL] [Abstract][Full Text] [Related]
69. Tacrine for Alzheimer's disease.
Qizilbash N; Birks J; Lopez Arrieta J; Lewington S; Szeto S
Cochrane Database Syst Rev; 2000; (3):CD000202. PubMed ID: 10908463
[TBL] [Abstract][Full Text] [Related]
70. Withdrawal versus continuation of chronic antipsychotic drugs for behavioural and psychological symptoms in older people with dementia.
Declercq T; Petrovic M; Azermai M; Vander Stichele R; De Sutter AI; van Driel ML; Christiaens T
Cochrane Database Syst Rev; 2013 Mar; (3):CD007726. PubMed ID: 23543555
[TBL] [Abstract][Full Text] [Related]
71. Are cholinesterase inhibitors effective in the management of the behavioral and psychological symptoms of dementia in Alzheimer's disease? A systematic review of randomized, placebo-controlled trials of donepezil, rivastigmine and galantamine.
Rodda J; Morgan S; Walker Z
Int Psychogeriatr; 2009 Oct; 21(5):813-24. PubMed ID: 19538824
[TBL] [Abstract][Full Text] [Related]
72. Rivastigmine: a placebo controlled trial of twice daily and three times daily regimens in patients with Alzheimer's disease.
Feldman HH; Lane R;
J Neurol Neurosurg Psychiatry; 2007 Oct; 78(10):1056-63. PubMed ID: 17353259
[TBL] [Abstract][Full Text] [Related]
73. Transdermal rivastigmine: management of cutaneous adverse events and review of the literature.
Greenspoon J; Herrmann N; Adam DN
CNS Drugs; 2011 Jul; 25(7):575-83. PubMed ID: 21623641
[TBL] [Abstract][Full Text] [Related]
74. Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study.
Ballard C; Sauter M; Scheltens P; He Y; Barkhof F; van Straaten EC; van der Flier WM; Hsu C; Wu S; Lane R
Curr Med Res Opin; 2008 Sep; 24(9):2561-74. PubMed ID: 18674411
[TBL] [Abstract][Full Text] [Related]
75. A phase II study in patients with Alzheimer's disease to assess the preliminary efficacy and maximum tolerated dose of rivastigmine (Exelon).
Forette F; Anand R; Gharabawi G
Eur J Neurol; 1999 Jul; 6(4):423-9. PubMed ID: 10362894
[TBL] [Abstract][Full Text] [Related]
76. An efficacy and safety analysis of Exelon in Alzheimer's disease patients with concurrent vascular risk factors.
Kumar V; Anand R; Messina J; Hartman R; Veach J
Eur J Neurol; 2000 Mar; 7(2):159-69. PubMed ID: 10809936
[TBL] [Abstract][Full Text] [Related]
77. Rivastigmine patch for treatment of Alzheimer's disease in clinical practice in Thailand.
Kulkantrakorn K; Tanyakitpisal P; Towanabut S; Dejthevaporn C; Rangseekajee P; Pongpakdee S; Laptikultham S; Rodprasert K; Setthawatcharawanich S; Thinkhamrop B
Psychogeriatrics; 2013 Mar; 13(1):1-8. PubMed ID: 23551405
[TBL] [Abstract][Full Text] [Related]
78. A systematic review of the clinical effectiveness of donepezil, rivastigmine and galantamine on cognition, quality of life and adverse events in Alzheimer's disease.
Takeda A; Loveman E; Clegg A; Kirby J; Picot J; Payne E; Green C
Int J Geriatr Psychiatry; 2006 Jan; 21(1):17-28. PubMed ID: 16323253
[TBL] [Abstract][Full Text] [Related]
79.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
80.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]